UroGen Pharma URGN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's investing cash flow?
- UroGen Pharma (URGN) reported investing cash flow of -$20.69M in Q1 2026.
- How has UroGen Pharma's investing cash flow changed year-over-year?
- UroGen Pharma's investing cash flow increased by 20.3% year-over-year, from -$25.96M to -$20.69M.
- What is the long-term trend for UroGen Pharma's investing cash flow?
- Over 2 years (2021 to 2025), UroGen Pharma's investing cash flow has grown at a 289.0% compound annual growth rate (CAGR), from $4.07M to $61.56M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.